Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspect...
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
About this item
Full title
Author / Creator
Publisher
Japan: Japan : Springer Japan
Journal title
Language
English
Formats
Publication information
Publisher
Japan: Japan : Springer Japan
Subjects
More information
Scope and Contents
Contents
Sorafenib, a multikinase inhibitor targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis, is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC). This advance has shifted the paradigm of systemic treatment for HCC toward molecular targeted therapy (MTT). However, the disease-stabiliz...
Alternative Titles
Full title
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_748948408
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_748948408
Other Identifiers
ISSN
0944-1174
E-ISSN
1435-5922
DOI
10.1007/s00535-010-0270-0
